Voyager Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Voyager Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- VYGR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001640266
Board of directors
-
Alfred Sandrock · Director · President and CEOSince 2023
-
Catherine J. Mackey · DirectorSince 2023
-
George A. Scangos · DirectorSince 2023
-
Glenn Pierce · DirectorSince 2023
-
Grace Colon · DirectorSince 2023
-
James A. Geraghty · DirectorSince 2023
-
Jude Onyia · DirectorSince 2023
-
Michael J. Higgins · DirectorSince 2023
-
Nancy Vitale · DirectorSince 2023
-
Steven Hyman · DirectorSince 2023
Chief executives
Alfred Sandrock
· President and CEO
Dates unknown
Board connections
6 of this board's directors also sit on 9 other boards.
- via Michael J. Higgins and Steven Hyman
- via George A. Scangos
- via Michael J. Higgins
- via Grace Colon
- via James A. Geraghty
- via Catherine J. Mackey
- via James A. Geraghty
- via Michael J. Higgins
- via George A. Scangos
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 21, 2025 | Fahey Sandell Jacquelyn Officer (Chief Legal Officer) | Grant or award | +41,500 | — | — |
| Feb 21, 2025 | Ferguson Toby Officer (Chief Medical Officer) | Grant or award | +63,000 | — | — |
| Feb 21, 2025 | Jorgensen Nathan D. Officer (Chief Financial Officer) | Grant or award | +51,500 | — | — |
| Feb 21, 2025 | Carter Todd Alfred Officer (Chief Scientific Officer) | Grant or award | +46,000 | — | — |
| Feb 21, 2025 | Alfred Sandrock Director, Officer (President and CEO) | Grant or award | +145,000 | — | — |
| Feb 21, 2025 | Swartz Robin Officer (COO & CBO) | Grant or award | +71,250 | — | — |
| Feb 20, 2025 | Carter Todd Alfred Officer (Chief Scientific Officer) | Open-market sale | −3,305 | $4.26 | $14,079 |
| Feb 20, 2025 | Alfred Sandrock Director, Officer (President and CEO) | Open-market sale | −11,702 | $4.24 | $49,616 |
| Feb 20, 2025 | Swartz Robin Officer (COO & CBO) | Open-market sale | −3,894 | $4.25 | $16,550 |
| Feb 11, 2025 | Carter Todd Alfred Officer (Chief Scientific Officer) | Open-market sale | −5,413 | $4.45 | $24,088 |
| Feb 11, 2025 | Swartz Robin Officer (COO & CBO) | Open-market sale | −6,950 | $4.45 | $30,928 |
| Feb 11, 2025 | Alfred Sandrock Officer (President & CEO) | Open-market sale | −16,644 | $4.45 | $74,066 |
| Feb 11, 2025 | Fahey Sandell Jacquelyn Officer (Chief Legal Officer) | Open-market sale | −4,358 | $4.45 | $19,393 |
| Jan 14, 2025 | Swartz Robin Officer (COO & CBO) | Open-market sale | −3,087 | $5.09 | $15,713 |
| Jan 14, 2025 | Carter Todd Alfred Officer (Chief Scientific Officer) | Open-market sale | −1,191 | $5.13 | $6,110 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.